查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378628

肺癌診斷與篩檢市場：依測試類型、癌症類型、最終用戶、地區分類

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test Imaging Test (Computed Tomography scan, Positron Emission Tomography scan, Chest X-Ray, Others), Biopsy), By Cancer Type, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2023 年，全球肺癌診斷和篩檢市場將達到 24.587 億美元，預測期內（2023-2030 年）年複合成長率為 10.1%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 24.587 億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 10.10% 2030年市場規模預測 48.356 億美元
圖 1. 2023 年按測試類型分類的肺癌診斷和篩檢的全球市場佔有率(%)
肺癌診斷及篩檢市場-IMG1

肺癌是一種由肺部細胞分裂失控引起的疾病。作為其正常功能的一部分，細胞會分裂並自我複製更多。受損細胞不受控制的分裂會導致組織腫瘤，最終導致器官停止正常運作。肺癌始於肺部，通常發生於氣道（細支氣管或細支氣管）或小氣囊（肺泡）。從其他地方開始並擴散到肺部的癌症通常以它們開始的地方命名。肺癌的治療包括手術、射頻消融、放射線治療、化療、標靶藥物治療和免疫治療。該行業的主要參與者專注於開發技術先進的產品。因此，將此類先進產品引入市場預計將在預測期內推動全球肺癌診斷和篩檢市場的成長。

市場動態

該行業的主要參與者專注於開發用於各種外科手術的技術先進的設備、儀器和系統。因此，將此類先進產品引入市場預計將在預測期內推動全球肺癌診斷和篩檢市場的成長。例如，2021年5月，分子診斷、應用測試、學術和藥物研究的樣本和檢測技術提供者QIAGEN宣布，therascreen KRAS RGQ PCR試劑盒（therascreen KRAS Kit）將在獲得美國法規機構的核准後作為為了幫助識別肺癌(NSCLC) 患者，我們宣布推出具有擴展申請的伴隨診斷 (CDx)。

本研究的主要特點

  • 本報告對全球肺癌診斷和篩檢市場進行了詳細分析，顯示了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率。
  • 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球肺癌診斷和篩檢市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球肺癌診斷和篩檢市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過用於分析全球肺癌診斷和篩檢市場的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的和假設

  • 這項研究的目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • 影響分析
  • 最近測試啟動
  • 流行病學
  • 合併、收購和合作
  • 法規場景
  • 主要進展
  • PEST分析

第4章 全球肺癌診斷與篩檢市場－新型冠狀病毒感染疾病（COVID-19）影響分析

  • 經濟影響
  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 對需求和供給的影響

第5章 2018-2030年全球肺癌診斷與篩檢市場（依檢驗類型）

  • 生物標記測試
  • EGFR突變檢測
  • KRAS突變測試
  • ALK測試
  • HER2測試
  • 其他
  • 影像檢查
  • 電腦斷層掃描 (CT) 掃描
  • 正子斷層掃描 (PET) 掃描
  • 胸部X光檢查
  • 其他
  • 切片檢查

第6章 全球肺癌診斷與篩檢市場，依癌症類型，2018-2030

  • 非小細胞肺癌
  • 小細胞肺癌

第7章 全球肺癌診斷和篩檢市場，按最終用戶分類，2018-2030 年

  • 醫院相關實驗室
  • 獨立診斷實驗室
  • 癌症研究所
  • 其他

第8章 2018-2030年全球肺癌診斷與篩檢市場（按地區）

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭形勢

  • 公司簡介
    • Abbott
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology（Beijing）Co.,Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics

第10章 章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI4434

The global lung cancer diagnostic and screening market is estimated to be valued at US$ 2,458.7 million in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 2,458.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 10.10% 2030 Value Projection: US$ 4,835.6 Mn
Figure 1. Global Lung Cancer Diagnostic and Screening Market Share (%), By Test Type, 2023
Lung Cancer Diagnostic and Screening Market - IMG1

Lung cancer is a disease caused by uncontrolled cell division in lungs. Cells divide and make more copies of themselves as part of their normal function. The uncontrolled division of damaged cells results in tissue tumors, which eventually prevent organs from functioning properly. Lung cancer start in the lungs, commonly in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that begin in another location and spread to the lungs are typically named after the location of their origin. Lung cancer treatments include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy. Key players in the industry are focusing on the development of technologically advanced products. Thus, the introduction of such advanced products into the market is expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period.

Market Dynamics

The key players in the industry are focusing on the development of technologically advanced equipment, instruments, and systems for various surgical procedures. Thus, the introduction of such advanced products in the market is expected to drive growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in May 2021, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment.

Key features of the study:

  • This report provides an in-depth analysis of the global lung cancer diagnostic and screening market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology(Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global lung cancer diagnostic and screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer diagnostic and screening market.

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

  • By Test Type:
    • Biomarkers Test
    • EGFR Mutation Test
    • KRAS Mutation Test
    • ALK Test
    • HER2 Test
    • Others
    • Imaging Test
    • Computed Tomography (CT) scan
    • Positron Emission Tomography (PET) scan
    • Chest X-Ray
    • Others
    • Biopsy
  • By Cancer Type:
    • Non-small cell lung cancer
    • Small Cell Lung Cancer
  • By End User:
    • Hospital Associated Labs
    • Independent Diagnostic Laboratories
    • Cancer Research Institutes
    • Others
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Abbott
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology(Beijing)Co.,Ltd.
    • AstraZeneca
    • F.Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Test Type
    • Market Snippet, By Cancer Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Test Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Lung Cancer Diagnostic and Screening Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Biomarkers Test
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • EGFR Mutation Test
  • KRAS Mutation Test
  • ALK Test
  • HER2 Test
  • Others
  • Imaging Test
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Computed Tomography (CT) scan
  • Positron Emission Tomography (PET) scan
  • Chest X-Ray
  • Others
  • Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Non-small cell lung cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Small Cell Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Lung Cancer Diagnostic and Screening Market, By End User, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Associated Labs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Independent Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Cancer Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Lung Cancer Diagnostic and Screening Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Test Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Abbott
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Amgen Inc.,
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Lepu Medical Technology(Beijing)Co.,Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Laboratory Corporation of America Holdings.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories.
    • Myriad Genetics, Inc.
    • GRAIL, LLC.
    • DELFI Diagnostics

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact